Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Susana, Tovey, Holly, Bowen, Rebecca, Folkerd, Elizabeth, Kilburn, Lucy, McLachlan, Jennifer, Hall, Marcia, Tunariu, Nina, Attygalle, Ayoma, Lima, Joao Paulo Da Silveira Nogueira, Perry, Sophie, Chatfield, Peter, Hills, Margaret, Kaye, Stan, Attard, Gert, Dowsett, Mitch, Bliss, Judith M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013695/
https://www.ncbi.nlm.nih.gov/pubmed/33854564
http://dx.doi.org/10.1177/1758835920975352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013695/
https://www.ncbi.nlm.nih.gov/pubmed/33854564
http://dx.doi.org/10.1177/1758835920975352

Ejemplares similares